File manager

File manager - Edit - /home/adiance/mail/.spam/new/1689004486.M30985P11273.40-69-163-212.cprapid.com,S=12161,W=12313

Back
Return-Path: <21822-29269-151684-3997-rsinghal=adiance.com@mail.doblive.email> Delivered-To: adiance+spam@40-69-163-212.cprapid.com Received: from 40-69-163-212.cprapid.com by 40-69-163-212.cprapid.com with LMTP id if/qAMYprGQJLAAAeDY3lg (envelope-from <21822-29269-151684-3997-rsinghal=adiance.com@mail.doblive.email>) for <adiance+spam@40-69-163-212.cprapid.com>; Mon, 10 Jul 2023 15:54:46 +0000 Return-path: <21822-29269-151684-3997-rsinghal=adiance.com@mail.doblive.email> Envelope-to: rsinghal@adiance.com Delivery-date: Mon, 10 Jul 2023 15:54:46 +0000 Received: from [157.52.238.178] (port=48023 helo=papa.doblive.email) by 40-69-163-212.cprapid.com with esmtp (Exim 4.96) (envelope-from <21822-29269-151684-3997-rsinghal=adiance.com@mail.doblive.email>) id 1qItDm-0002vN-09 for rsinghal@adiance.com; Mon, 10 Jul 2023 15:54:45 +0000 DKIM-Signature: v=1; a=rsa-sha1; c=relaxed/relaxed; s=k1; d=doblive.email; h=Mime-Version:Content-Type:Date:From:Reply-To:Subject:To:Message-ID; i=Eyesightsupplement@doblive.email; bh=Z2Y8qrOmSWxUe0+bxATxODMFJMA=; b=JqhyDDAzAiK7GT5LRYWwMn3iY466qRz7g5jApVm1dQC6gv80OuQPUYeiNSmmk0GrlFWx/WuxxGHx 4VV53vnk7PIGACO0Y8I6UBiIia6afgJM9thRPTnggJQ7+QGCA+oU+0c33Zw+krDEk8js533qnP9C Jx1osDiRJ41MGg3YuR0= DomainKey-Signature: a=rsa-sha1; c=nofws; q=dns; s=k1; d=doblive.email; b=IKQ8dycyKh/nwQdsiI3UjcJ0BlnoxxdmjVsouQsHuUYkqZH1EvQjRt94k2pDQoKXUUHTcvTJtQ27 X7HgKPIOm7OZvnti+cRyG6qh8PBVFQuMFqQ3fm640gNiIn14COzJGcCSMo4mrZ8YYsiW1s0dXwuS RIMoOWfOkXGVNYsX7EQ=; Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="2d31403a26fc833b6c18e2854f56d2d5_7255_25084" Date: Mon, 10 Jul 2023 17:53:17 +0200 From: "Eyesight supplement" <Eyesightsupplement@doblive.email> Reply-To: "Eyesight supplement" <Eyesightsupplement@doblive.email> To: <rsinghal@adiance.com> Message-ID: <9s1c0ttas6q817at-nqym8fuy8knxd1w4-7255-25084@doblive.email> X-Spam-Status: Yes, score=24.4 X-Spam-Score: 244 X-Spam-Bar: ++++++++++++++++++++++++ X-Spam-Report: Spam detection software, running on the system "40-69-163-212.cprapid.com", has identified this incoming email as possible spam. The original message has been attached to this so you can view it or label similar future email. If you have any questions, see root\@localhost for details. Content preview: Revoke vision loss with this cream? http://doblive.email/ccg54GuZdEkquvl6GfGEcBWan574uT1q1KHn_IJ8Nn2aOMY http://doblive.email/RHE6AkxomrmOSLbMr_GeEQg__hyAhQSwnhAsENw5XLLWnnYJ Content analysis details: (24.4 points, 5.0 required) pts rule name description ---- ---------------------- -------------------------------------------------- 1.9 URIBL_ABUSE_SURBL Contains an URL listed in the ABUSE SURBL blocklist [URIs: doblive.email] 5.0 URIBL_BLACK Contains an URL listed in the URIBL blacklist [URIs: doblive.email] 4.5 URIBL_DBL_SPAM Contains a spam URL listed in the Spamhaus DBL blocklist [URIs: doblive.email] -0.0 SPF_PASS SPF: sender matches SPF record 0.0 HTML_FONT_LOW_CONTRAST BODY: HTML font color similar or identical to background 0.0 PP_MIME_FAKE_ASCII_TEXT BODY: MIME text/plain claims to be ASCII but isn't 0.0 HTML_MESSAGE BODY: HTML included in message -0.1 DKIM_VALID_AU Message has a valid DKIM or DK signature from author's domain 0.1 DKIM_SIGNED Message has a DKIM or DK signature, not necessarily valid -0.1 DKIM_VALID_EF Message has a valid DKIM or DK signature from envelope-from domain -0.1 DKIM_VALID Message has at least one valid DKIM or DK signature 2.4 RAZOR2_CF_RANGE_51_100 Razor2 gives confidence level above 50% [cf: 100] 1.7 RAZOR2_CHECK Listed in Razor2 (http://razor.sf.net/) 2.0 PYZOR_CHECK Listed in Pyzor (https://pyzor.readthedocs.io/en/latest/) -0.0 T_SCC_BODY_TEXT_LINE No description available. 2.0 RDNS_NONE Delivered to internal network by a host with no rDNS 5.0 KAM_VERY_BLACK_DBL Email that hits both URIBL Black and Spamhaus DBL 0.0 FSL_BULK_SIG Bulk signature with no Unsubscribe X-Spam-Flag: YES Subject: *SPAM* Revoke vision loss with this cream? --2d31403a26fc833b6c18e2854f56d2d5_7255_25084 Content-Type: text/plain; Content-Transfer-Encoding: 8bit Revoke vision loss with this cream? http://doblive.email/ccg54GuZdEkquvl6GfGEcBWan574uT1q1KHn_IJ8Nn2aOMY http://doblive.email/RHE6AkxomrmOSLbMr_GeEQg__hyAhQSwnhAsENw5XLLWnnYJ Around 19% of people diagnosed with lung cancer survive five years from diagnosis, though prognosis varies based on the stage of the disease at diagnosis and the type of lung cancer. Prognosis is better for people with lung cancer diagnosed at an earlier stage; those diagnosed at the earliest TNM stage, IA1 (small tumor, no spread), have a two-year survival of 97% and five-year survival of 92%. Those diagnosed at the most-advanced stage, IVB, have a two-year survival of 10% and a five-year survival of 0%. Five-year survival is higher in women (22%) than men (16%). Women tend to be diagnosed with less-advanced disease, and have better outcomes than men diagnosed at the same stage. Average five-year survival also varies across the world, with particularly high five-year survival in Japan (33%), and five-year survival above 20% in 12 other countries: Mauritius, Canada, the US, China, South Korea, Taiwan, Israel, Latvia, Iceland, Sweden, Austria, and Switzerland. SCLC is particularly aggressive. 10–15% of people survive five years after a SCLC diagnosis. As with other types of lung cancer, the extent of disease at diagnosis also influences prognosis. The average person diagnosed with limited-stage SCLC survives 12–20 months from diagnosis; with extensive-stage SCLC around 12 months. While SCLC often responds initially to treatment, most people eventually relapse with chemotherapy-resistant cancer, surviving an average 3–4 months from the time of relapse. Those with limited stage SCLC that go into complete remission after chemotherapy and radiotherapy have a 50% chance of brain metastases developing within the next two years – a chance reduced by prophylactic cranial irradiation. Several other personal and disease factors are associated with improved outcomes. Those diagnosed at a younger age tend to have better outcomes. Those who smoke or experience weight loss as a symptom tend to have worse outcomes. Tumor mutations in KRAS are associated with reduced survival --2d31403a26fc833b6c18e2854f56d2d5_7255_25084 Content-Type: text/html; Content-Transfer-Encoding: 8bit <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><meta http-equiv="X-UA-Compatible" content="IE=edge"/><meta name="viewport" content="width=decive-width, initial-scale=1.0"> <title>Newsletter</title> </head> <body><a href="http://doblive.email/_5z05iaGCDPQ-sy-yrfEQbjiVTgU2r57YCLjbKiUfZzJwH1U"><img src="http://doblive.email/4ff3253a302e1e9961.jpg" /><img height="1" src="http://www.doblive.email/eAyCEK62DwPR8Xh6oB2LEJi6BwIWI8Ki-oRyxCHR13JcMsHd" width="1" /></a> <center>  <div style="max-width:100%;height:auto;width:500px;"> <div style="width:500px;font-size:17px; font-family:cambria;text-align:left;border:2px solid #000000;Padding:10px;">This is a groundbreaking vision loss discovery you shouldn’t miss.<br /> <br /> <a href="http://doblive.email/ccg54GuZdEkquvl6GfGEcBWan574uT1q1KHn_IJ8Nn2aOMY" http:="" microsoft.com="" rel="sponsored" style="font-weight:bold;" target="blank">Academic Institutions like the Santa Clara and Suffolk Universities</a> confirm that these substances have been found to ameliorate vision loss symptoms, nurture the outer layers of the eyes, heal the inner parts and eventually improve eyesight altogether.<br /> <br /> When combined with 30ml of water, they form a gel-like substance that is extremely rich in eye beneficial properties.<br /> <br /> <a href="http://doblive.email/ccg54GuZdEkquvl6GfGEcBWan574uT1q1KHn_IJ8Nn2aOMY" http:="" microsoft.com="" rel="sponsored" style="font-weight:bold;" target="blank">Follow the instructions below.</a><br /> <br /> <a href="http://doblive.email/ccg54GuZdEkquvl6GfGEcBWan574uT1q1KHn_IJ8Nn2aOMY" http:="" microsoft.com="" rel="sponsored" target="blank"><img src="http://doblive.email/f15fd10f28a4594179.gif" /></a><br /> <br /> <b>PS:</b> My mother has suffered from MAD and this solution not only stopped the disease from getting worse but even helped her see more clearly.<br /> <br /> I was amazed the other day, when I was driving her home and she could read a billboard ad from a distance she couldn’t see anything at all just 2 months ago.<br />  </div> <br /> <br /> <br /> <br /> <br /> <br /> <br />   <div style="font-size:12px; font-family:arial;"><a href="http://doblive.email/vGsZnIrPHxaG_-vD9NJoeYlk2JB2ARMvohJ-4oc-3VhFg-Q" http:="" microsoft.com="" rel="sponsored" style="font-weight:bold;" target="blank">Click Here</a> to Unsubscribe write to<br /> 200 Continental Drive, Suite 401, Newark, DE, 19713, US</div> <br /> <br /> <br /> <br /> <span style="color:#FFFFFF;font-size:9px;">Around 19% of people diagnosed with lung cancer survive five years from diagnosis, though prognosis varies based on the stage of the disease at diagnosis and the type of lung cancer. Prognosis is better for people with lung cancer diagnosed at an earlier stage; those diagnosed at the earliest TNM stage, IA1 (small tumor, no spread), have a two-year survival of 97% and five-year survival of 92%. Those diagnosed at the most-advanced stage, IVB, have a two-year survival of 10% and a five-year survival of 0%. Five-year survival is higher in women (22%) than men (16%). Women tend to be diagnosed with less-advanced disease, and have better outcomes than men diagnosed at the same stage. Average five-year survival also varies across the world, with particularly high five-year survival in Japan (33%), and five-year survival above 20% in 12 other countries: Mauritius, Canada, the US, China, South Korea, Taiwan, Israel, Latvia, Iceland, Sweden, Austria, and Switzerland. SCLC is particularly aggressive. 10–15% of people survive five years after a SCLC diagnosis. As with other types of lung cancer, the extent of disease at diagnosis also influences prognosis. The average person diagnosed with limited-stage SCLC survives 12–20 months from diagnosis; with extensive-stage SCLC around 12 months. While SCLC often responds initially to treatment, most people eventually relapse with chemotherapy-resistant cancer, surviving an average 3–4 months from the time of relapse. Those with limited stage SCLC that go into complete remission after chemotherapy and radiotherapy have a 50% chance of brain metastases developing within the next two years – a chance reduced by prophylactic cranial irradiation. Several other personal and disease factors are associated with improved outcomes. Those diagnosed at a younger age tend to have better outcomes. Those who smoke or experience weight loss as a symptom tend to have worse outcomes. Tumor mutations in KRAS are associated with reduced survival</span><br /> <br /> <br /> <br /> <br />   <div style="font-size:12px; font-family:arial;"><a href="http://doblive.email/RHE6AkxomrmOSLbMr_GeEQg__hyAhQSwnhAsENw5XLLWnnYJ" http:="" microsoft.com="" rel="sponsored" style="font-weight:bold;" target="blank">Click Here</a> to Unsubscribe write to<br /> 1288 Hilltop Haven Drive Riverdale, NJ 07442</div> <br />  </div> <img src="Imagefor1px.png" /></center> </body> </html> --2d31403a26fc833b6c18e2854f56d2d5_7255_25084--

| ver. 1.4 | Github | . | PHP 7.3.33 | Generation time: 0.07 | proxy | phpinfo | Settings